ArticleBMC cancer2025
A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of prognostic biomarkers related to epithelial-mesenchymal transition and anoikis in hepatocellular carcinoma using transcriptomics and single-cell sequencing.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Death and tumor recurrence are both important adverse prognostic factors for hepatocellular carcinoma(HCC) patients. This article aims to discuss the risk factors for recurrence and death in patients with HCC after R0 resection, and to establish a nomogram model for predicting the recurrence and death of HCC patients.A total of 224 HCC patients after R0 resection were enrolled and divided into a training cohort (n = 149) and a validation cohort (n = 75) The risk factors for recurrence and death were determined based on cox regression analysis. A nomogram containing independent risk predictors was established and validated.The recurrence rate of 224 cases of HCC after R0 resection was 43.30%. The high expression of interleukin-41(IL41) (HR = 2.446, P = 0.000), intratumoral artery (HR = 1.862, P = 0.005), and MVI1 subgroup of microvascular invasion(MVI) grade (HR = 1.541, P = 0.031) are independent risk factors associated with recurrence after resection of HCC. The mortality rate was 15.63%. The high expression of IL-41 (HR = 4.679, P = 0.000), tumor size ≥ 5 cm (HR = 3.745, P = 0.001), and Aspartate transaminase(AST) concentration 45-90u/L (HR = 2.837, P = 0.015) are independent risk factors associated with mortality. Interleukin-41(IL-41), microvascular invasion(MVI), and intratumoral artery are independent risk factors for recurrence after resection of hepatocellular carcinoma. IL-41, tumor size, and Aspartate transaminase(AST) are independent risk factors for death after resection of hepatocellular carcinoma. We developed and validated two multivariate nomograms, and conducted validation. The nomogram models have achieved ideal results in predicting the recurrence and death of HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.